Every 8-K that Humacyte, Inc. (HUMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HUMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUMA filings page.
Humacyte, Inc. reported second quarter 2026 results, highlighting clinical and commercial progress alongside continued losses. For the quarter ended June 30, 2026, total revenue was $406,000, up from $301,000 a year earlier, driven by Symvess product revenue of $0.4 million versus $0.1 million in 2025.
Loss from operations was $27.0 million, with a net loss of $36.8 million compared with a net loss of $37.7 million in the prior-year quarter. For the first six months of 2026, the company recorded a net loss of $54.4 million versus net income of $1.5 million in the first half of 2025.
Humacyte ended June 30, 2026 with $79.9 million in cash and cash equivalents, up from $50.5 million at December 31, 2025, and stockholders’ equity of $31.3 million, up from $3.1 million. The company reported breakthrough Phase 3 results for its acellular tissue engineered vessel in dialysis access, plans a supplemental BLA filing in the second half of 2026, and is preparing a Phase 2a CABG study under an accepted IND.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price closed below the $1.00 per share minimum for 30 consecutive business days ended July 30, 2026, violating Nasdaq Listing Rule 5450(a)(1).
Under Nasdaq Listing Rule 5810(c)(3)(A), Humacyte has 180 calendar days, until January 27, 2027, to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days. The notice has no immediate effect on the Nasdaq Global Select Market listing, trading symbol HUMA, or on business operations, while the company monitors its stock price and evaluates options.
Humacyte, Inc. entered into an underwriting agreement for a public offering of its common stock. The company is issuing 47,619,048 shares at a public offering price of $1.05 per share, with underwriters holding a 30‑day option to buy up to 7,142,857 additional shares.
Gross proceeds are expected to be $50 million, with net proceeds of about $46.80 million, or $53.85 million if the option is fully exercised. Humacyte plans to use the cash to commercialize its Symvess product, support a planned Biologics License Application supplement in a hemodialysis indication, advance its pipeline, and for working capital and general corporate purposes.
Humacyte, Inc. reported positive interim Phase 3 results for its acellular tissue engineered vessel (ATEV) in female dialysis patients. In the V012 study’s prespecified analysis of the first 80 patients, ATEV met the primary endpoint, delivering an average of 91 more catheter-free days than autologous arteriovenous fistula, the current standard of care.
ATEV patients achieved 220 catheter-free days versus 129 with fistula (p=0.00070) and showed substantially lower infection rates. Based on these results, enrollment will stop and follow-up will continue, and Humacyte plans to file a supplemental Biologic License Application with the FDA in the second half of 2026 for high-risk end-stage kidney disease patients.
Humacyte, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders approved an amendment to the Certificate of Incorporation increasing authorized common shares from 350,000,000 to 550,000,000, which became effective upon filing in Delaware on June 9, 2026.
As of the April 23, 2026 record date, 222,019,108 common shares were outstanding, and 127,474,086 shares, or about 57.41%, were represented to form a quorum. Stockholders elected three Class II directors, approved on an advisory basis the compensation of named executive officers and chose to hold future say-on-pay votes annually.
They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and formally approved the increase in authorized common stock. No broker non-votes were recorded on the auditor ratification or share authorization proposals.
Humacyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company had previously been notified that its common stock traded below the required $1.00 per share bid price for 30 consecutive business days ended May 1, 2026.
To cure the issue, Humacyte’s stock needed to close at or above $1.00 for at least 10 consecutive business days before November 2, 2026. On June 5, 2026, Nasdaq informed the company that this condition was met and that its listing on The Nasdaq Global Select Market is now in good standing, with the matter considered closed.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price was below the required $1.00 per share for 30 consecutive business days ended May 1, 2026, putting it out of compliance with Nasdaq Listing Rule 5450(a)(1).
The company has 180 calendar days, until November 2, 2026, for its closing bid price to be at least $1.00 per share for a minimum of 10 consecutive business days to regain compliance. Trading of the stock and the company’s operations and SEC reporting continue unchanged for now, but there is explicit delisting risk if compliance is not restored.
Humacyte, Inc. entered a Third Amendment to its distribution agreement with Fresenius Medical Care, giving Humacyte the sole right to develop, manage regulatory matters for, and commercialize its 6 millimeter acellular tissue engineered vessel, branded Symvess, on a worldwide basis.
In return, Humacyte will pay Fresenius low-single-digit royalties on net sales of Symvess outside the U.S., after a two-year royalty-free period following launch in each country, while existing U.S. royalty rates from mid-single digits to low double digits remain in place and Fresenius stays obligated to adopt Symvess as a standard of care where supported. Humacyte highlights that this realignment supports its planned international expansion and potential indication-specific partnerships, while Symvess currently holds FDA approval only for extremity vascular trauma and remains investigational for other uses.
Humacyte, Inc. is raising $20 million through a registered direct offering of 25,000,000 shares of common stock at $0.80 per share. After placement fees and expenses, net proceeds are expected to be about $18.4 million.
The cash will support commercialization of Symvess in the vascular trauma indication, a planned Biologics License Application supplement for a hemodialysis use, related Phase 3 activities, broader pipeline development, and general corporate purposes. The offering, led by institutional investors, is expected to close on or about March 20, 2026, subject to customary conditions.
Humacyte, Inc. is suspending and terminating its at-the-market equity program prospectus that had allowed sales of up to $60 million in common stock under a sales agreement with TD Cowen, while leaving the underlying agreement in place for potential future use with a new prospectus.
Based on preliminary estimates for the year ended December 31, 2025, the company expects about $50.9 million in cash, cash equivalents and restricted cash, total revenue of roughly $2.0 million including $1.4 million in product revenue, and 61 Symvess unit sales. Operationally, Humacyte obtained a minimum Symvess purchase commitment of approximately $1.48 million in the Kingdom of Saudi Arabia tied to a potential joint venture and license, and filed a Marketing Authorization Application in Israel for Symvess in vascular trauma. The company also released an investor presentation and updated its risk factors to reflect ongoing losses, funding needs, regulatory and clinical trial uncertainties, pricing pressures and data-privacy compliance risks.
Humacyte, Inc. entered into a Sales Agreement with TD Securities (USA) LLC, as agent, that permits it to offer and sell, from time to time, its common stock with an aggregate offering price of up to $60,000,000 in an at the market offering under a previously filed and effective registration statement.
TD Securities (USA) LLC, referred to as TD Cowen, will use commercially reasonable efforts to execute sales on the Nasdaq Global Select Market or other permitted markets, and may also sell shares in negotiated transactions if expressly authorized. TD Cowen will receive a commission of up to 3.0% of the gross proceeds from any share sales. Humacyte plans to use any net proceeds to fund commercialization of Symvess® in the vascular trauma indication, advance its product candidates, and for working capital and general corporate purposes. The agreement can end once all shares are sold or be terminated by either party on ten days’ notice, with additional termination rights for TD Cowen in certain circumstances.
Humacyte, Inc. entered into a senior secured term loan facility of up to $77,500,000 maturing on December 1, 2029 with Avenue Venture Opportunities Fund II, L.P. The facility includes a $40 million first tranche funded at closing, a $12.5 million delayed draw available between October 1, 2026 and March 31, 2027 subject to revenue, regulatory and liquidity conditions, and a $25 million delayed draw available between July 1, 2027 and June 30, 2028 at the lenders’ discretion, also subject to conditions.
The term loans bear interest at the greater of 11.50% or the Wall Street Journal Prime Rate plus 4.50%, with interest-only payments and principal amortization starting December 1, 2027 or, if the second tranche is drawn, December 1, 2028. Humacyte granted Avenue a warrant expiring December 15, 2030 to purchase shares of common stock based on up to $5,037,500 divided by an exercise price set as the lower of $1.28 or the lowest cash sale price in certain equity offerings through March 31, 2026, subject to adjustments, and lenders may convert up to $2,500,000 of loan principal into common stock at 130% of the warrant price. The loans are secured by substantially all assets, carry 3%, 2% or 1% prepayment premiums depending on timing, and proceeds may be used for working capital, general business needs and repayment of existing indebtedness.
Humacyte, Inc. will issue 5,725,190 shares of common stock and pay $38 million in cash to end a revenue interest purchase agreement and a related option agreement with certain investment funds, in satisfaction of all obligations under those contracts.
The $38 million payment is expected to be funded with proceeds from a new credit facility, while the shares will be issued in a registered direct offering under an existing shelf registration statement. The offering is expected to close on December 15, 2025, subject to customary closing conditions.
Humacyte, Inc. reported that it has terminated its Open Market Sale Agreement™ with Jefferies LLC. This agreement had allowed the company to offer and sell shares of its common stock from time to time, with an aggregate offering price of up to $80,000,000 through Jefferies acting as sales agent. The company delivered a notice of termination on November 21, 2025, and the termination becomes effective 10 days after that date. Humacyte states that it is not subject to any termination penalties in connection with ending this agreement.
Humacyte, Inc. furnished an 8‑K announcing that it issued a press release with financial results for its fiscal third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed “filed” under the Exchange Act.
Humacyte’s securities trade as HUMA (common stock) and HUMAW (warrants) on Nasdaq.
Humacyte, Inc. filed an 8-K reporting a material event that includes a Securities Purchase Agreement dated October 6, 2025 between the company and certain investors, and a Placement Agent Agreement dated October 6, 2025 with D. Boral Capital LLC. The filing also lists a Form of Warrant, legal opinion and consent from Covington & Burling LLP, and a press release dated October 7, 2025. The document identifies the company’s Chief Financial Officer, Chief Corporate Development Officer and Treasurer as signatory roles. No transaction amounts, share counts, or pricing terms are disclosed in the provided text.
Humacyte, Inc. reported a material event on an Form 8-K documenting Amendment No. 2 to a Revenue Interest Purchase Agreement executed on September 17, 2025. The amendment names the parties as Humacyte Global, Inc., Humacyte, Inc. and the purchasers TPC Investments III LP, TPC Investment Solutions LP and Hook SA LLC.
The filing indicates the inclusion of the amendment as an exhibit and an Inline XBRL cover page file. No financial terms, changes to covenants, or quantitative impacts were disclosed in the provided text, so the filing primarily records the contractual amendment rather than operational results.
Humacyte, Inc. furnished a press release reporting its financial results for the fiscal second quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Current Report, but the body of the Form 8-K does not include the underlying financial figures or tables.
The filing explicitly states that the information, including the exhibit, "shall not be deemed filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference in other filings except by specific reference. The report also identifies the company as an emerging growth company and lists its securities as Common Stock (HUMA) and Redeemable Warrants (HUMAW) on Nasdaq. The filing includes Exhibit 99.1 and the Cover Page Interactive Data File (Exhibit 104).